文献速递临床试验与 GCP基础与转化研究

阿司匹林用于结直肠癌肝转移二级预防(ASAC试验):多中心随机安慰剂对照试验方案

Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial.
PubMed 文献 · Trials · 2021-09-20

ASAC试验是斯堪的纳维亚多中心、双盲、随机、安慰剂对照研究,旨在评估低剂量阿司匹林(ASA)160 mg每日一次辅助治疗能否改善结直肠癌肝转移(CRCLM)术后患者的无病生存。计划纳入至多800例肝转移切除术患者,随机分配至ASA组或安慰剂组,治疗3年或直至疾病复发,随访按标准诊疗和国家指南进行。该试验将首次评估ASA在CRCLM复发和生存中的潜在获益,并评估健康相关生活质量和成本效益。

要点

  • ASAC试验评估低剂量阿司匹林160 mg每日一次辅助治疗对CRCLM术后无病生存的影响。
  • 计划纳入至多800例肝转移切除术患者,随机双盲安慰剂对照,治疗3年或直至复发。
  • 次要目标包括健康相关生活质量和成本效益评估。

核心结论

  • ASAC试验将首次评估阿司匹林作为辅助治疗在结直肠癌肝转移复发和生存中的潜在有益作用。

研究设计与样本

  • 斯堪的纳维亚多中心、双盲、随机、安慰剂对照研究,计划纳入至多800例接受肝转移切除术的CRCLM患者。

关键数值与推荐

  • 实验组(Arm#1)接受阿司匹林(ASA)160 mg每日一次,对照组(Arm#2)接受安慰剂,治疗3年或直至疾病复发。
  • 患者在挪威、瑞典和丹麦所有主要肝胆外科单位招募,随访按标准诊疗和国家指南进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colorectal cancer is one the most common cancers in the western world with increasing incidence. Approximately 50% of the patients develop liver metastases. Resection of liver metastases is the treatment of choice although almost half of the resected patients get recurrence in the liver. METHODS: The ASAC trial is a Scandinavian, multicentre, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose aspirin (acetylsalicylic acid (ASA)) can improve disease-free survival in patients treated for colorectal cancer liver metastases (CRCLM). Up to 800 patients operated for CRCLM will be randomized to Arm#1 ASA 160 mg once daily or Arm#2 Placebo, for a period of 3 years or until disease recurrence. The patients will be recruited at all major hepatobiliary surgical units in Norway, Sweden and Denmark and have follow-up according to standard of care and the National Guidelines. DISCUSSION: The ASAC trial will be the first clinical interventional trial to assess the potential beneficial role of ASA in recurrence of CRCLM and survival. ASA is an inexpensive, well-tolerated and easily accessible drug that will be highly potential as adjuvant drug in secondary prevention of CRCLM if the study shows a beneficial effect. We will also determine the effect of ASA as adjuvant treatment on Health-Related Quality of Life and the cost-effectiveness. TRIAL REGISTRATION: ClinicalTrials.gov NCT03326791 . Registered on 31 October 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yaqub S, Bjørnbeth BA, Angelsen JH, et al. Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial. Trials. 2021. PMID: 34544470. doi:10.1186/s13063-021-05587-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。